22q11.2 microdeletion Fact sheet

- Microdeletion (loss of genetic information) of about 3 million bases (3 megabases) on the long arm of chromosome 22 in position 11
- Associated with DiGeorge syndrome and velo-cardio-facial syndrome
- Occurs spontaneously in more than 90% of those affected, can also be inherited in 6% – 28%¹ of the cases
- Clinical abnormalities, particularly heart defects, may have different manifestations, depending on the severity of the disease

Determination of a 22q11.2 microdeletion

Non-invasive prenatal test to exclude or detect a 22q11.2 microdeletion² for singleton pregnancy (using the proprietary & CE-marked *dmap* software)

NEW - can be selected in combination with both PrenaTest® options 2 and 3

Test result provided only with cffDNA level ≥ 11% in addition to other quality criteria

If quality criteria are not met: no repetition/no invoicing

NEW - **post analysis possible** with PrenaTest® data ≤ 3 months; without new blood sample **Test results require 2 additional working days**³ after analysis of test options 2/3 - to be invoiced separately

Test accuracy of the PrenaTest® for the determination of the 22q11.2 microdeletion

Phase 1 – A total of 469 samples were tested, of which 175 (37.3%) met the quality criteria. Three positive samples with a 22q11.2 microdeletion were correctly determined (3/3, 100%). All negative samples were correctly classified (172/172, 100%). There were no false-positive or false-negative results.

Phase 2 – In a final internal blinded study, 20 samples from Phase 1 were examined. All samples were classified correctly. Due to the low number of cases a concrete test sensitivity and specificity cannot be derived.

Limitations

cffDNA level

The detection or exclusion of a 22q11.2 microdeletion is currently only possible for specimens which have a cffDNA level of at least 11% (in addition to other quality criteria).

Mother is the carrier of the microdeletion

It is possible that the mother is the carrier of the 22q11.2 microdeletion. This can lead to discordant (false-positive) test results.

Size of the microdeletion

In more than 85% of affected persons, the deletion includes a region measuring approx. 2.5 megabases in the 22q11.2 region of chromosome 22. This region is investigated with the PrenaTest®. A small percentage of affected persons has an even smaller deletion or point mutation in the affected region which cannot be detected with the PrenaTest®. This can lead to discordant (false-negative) test results.

Microduplication in the investigated gene region

In the investigated gene region of chromosome 22, microduplications can also occur. These are not determined with the PrenaTest®.

Reasons for the genetic examination

This examination is particularly useful in cases of abnormalities on ultrasound, for example during organ screening, which may correlate with a DiGeorge

- Congenital heart defect
- Detection of an aberrant subclavian artery
- Kidney malformation
- Growth retardation
- Cleft lip and palate
- Increased nuchal translucence
- Small thymus

Clinical lab routine

- Over 1,000 tests successfully performed since June 2016
- So far no discordant results based on feedback from doctor
- But: false-negative or false positive results cannot be excluded

Please note:

The cffDNA level is highly individual and increases in later gestational weeks. Therefore it is possible that due to a cffDNA level that is too low, no test result can be achieved. A new blood sample is not requested provided the cffDNA level is sufficient for determining fetal trisomies 13, 18, 21 as well as gonosomal aneuploidies.

Week 12 – 14	Week 19 – 23
Samples with o	cffDNA ≥ 11%
47.25%	52.78%
Samples with	effDNA < 11%
53.75%	47.22%



LifeCodex

¹ Fernández L et al. Higher frequency of uncommon 1.5-2 Mb deletions found in familial cases of 22q11.2 deletion syndrome. Am J Med Genet A. 2005 Jul 1;136(1):71-5.

² OMIM# of the disease: 188400 (DGS), 192430 (VCFS)

³ Monday to Friday, except holidays